taken together, we show that AKR1C1 is a potent inducer of NSCLC metastasis. Our study uncovers the active function of AKR1C1 as a key component of the STAT3 pathway, which promotes lung cancer metastasis, and highlights a candidate therapeutic target to potentially improve the survival of NSCLC patients with metastatic disease.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: